Paysign beats Q1 revenue estimates on patient affordability programs

Paysign

12/05/2026 21:22

Overview

US patient affordability platform's Q1 revenue rose 51% yr/yr, beating analyst expectations

Adjusted EPS for Q1 rose to $0.09, more than doubling from prior year

Growth driven by pharma patient affordability and plasma donor compensation programs

Outlook

Paysign sees Q2 revenue of $26.2 mln–$26.7 mln and full-year revenue of $106.5 mln–$110.5 mln

Company expects Q2 gross margin of 60.0%–62.0% and full-year gross margin of 60%–62%

Paysign expects to exit Q2 with 147–150 active patient affordability programs and 555–560 plasma centers

Result Drivers

PHARMA PROGRAM EXPANSION - Revenue growth in pharma segment driven by 45 net new patient affordability programs and higher management, setup, and processing fees

PLASMA CENTER GROWTH - Plasma revenue rose on addition of 89 net plasma centers and higher average revenue per center

MIX SHIFT TO PHARMA - Gross margin improved due to a greater mix of higher-margin pharma revenue

Company press release: ID:nBw3GFrk0a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$28.04 mln
$27.008 mln (5 Analysts)
Q1 EPS
$0.09
Q1 Net Income
$5.44 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the business support services peer group is "buy"

Wall Street's median 12-month price target for Paysign Inc is $9.00, about 34.3% above its May 11 closing price of $6.70

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 23 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)